Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.415 USD | -0.82% | +0.65% | -39.77% |
Jun. 05 | Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis | CI |
Jun. 03 | Lucien Selce Sends Letter to Aurinia shareholders | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.77% | 779M | |
+18.35% | 125B | |
+14.21% | 109B | |
-2.20% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.48% | 16.64B | |
+0.19% | 13.45B | |
+23.33% | 11.32B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing